• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

FDA panel votes against BD Lutonix drug-coated balloon for below-the-knee

February 18, 2021 By Danielle Kirsh

BD-logoAn FDA advisory panel voted against a favorable recommendation for BD‘s Lutonix catheter-based, drug-coated balloon for use below the knee.

The FDA’s Circulatory System Devices Advisory Panel yesterday voted 15-to-2 in favor of the issue of safety when Lutonix is used as intended and voted 15-to-2 against the issue of a reasonable assurance of effectiveness. The panel also voted 14-to-3 against whether the benefits outweigh the risks. There was one abstained vote for each measure.

The Lutonix 014 Drug-Coated Balloon PTA catheter had a proposed indication for use for percutaneous transluminal angioplasties of obstructive de novo or non-stented restenotic lesions in popliteal, tibial and perineal arteries up to 320 mm in length. The advisory panel convened to provide input and recommendations to the FDA to support the agency’s review of Lutonix in the treatment of below-the-knee arteries in patients with critical limb ischemia.

Information presented during the panel meeting included six-month primary endpoint data and safety data out to 36 months from the Lutonix BTK IDE pivotal trial that enrolled 462 patients from the U.S., Europe, Canada and Japan in a multicenter, prospective, single-blind, randomized trial.

“While the panel’s vote on the question of safety was favorable, their votes on effectiveness and risk-benefit focused on study design and the challenges of executing a trial over eight years in this complex patient population,” said J.D. Meler, VP of medical affairs for BD’s peripheral intervention business.

“We thank FDA and the panel for the opportunity to bring these important data to light in this area of unmet need, and thank the clinicians, patients and advocates who shared their personal thoughts and experiences with the panel,” Meler said in a news release.

The FDA denied the Lutonix drug-coated balloon catheter’s approval for use below the knee in early 2019. At the time, the agency said that its preliminary review of long-term follow-up data found a “potentially concerning signal” of increased long-term mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices compared to those treated with bare devices.

 

Filed Under: Catheters, Research & Development Tagged With: BD

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS